|
Jan. 07, 2026 |
|
|
Jan. 07, 2026 |
|
|
jRCT2031250618 |
ROH-201 ophthalmic solution phase II clinical trial in patients with vernal keratoconjunctivitis |
|
ROH-201 ophthalmic solution phase II clinical trial in patients with vernal keratoconjunctivitis |
Mantani Tomomi |
||
ROHTO Pharmaceutical Co., Ltd. |
||
6-5-4, Kunimidai, Kizugawa, Kyoto 619-0216, Japan |
||
+81-774-71-8802 |
||
rohtocl@rohto.co.jp |
||
Mantani Tomomi |
||
ROHTO Pharmaceutical Co., Ltd. |
||
6-5-4, Kunimidai, Kizugawa, Kyoto 619-0216, Japan |
||
+81-774-71-8802 |
||
rohtocl@rohto.co.jp |
Pending |
Jan. 07, 2026 |
||
| 12 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
Patients for whom written informed consent was obtained from the subject or a legally authorized representative |
||
Patients who require contact lens wear |
||
| 6age old over | ||
| No limit | ||
Both |
||
Vernal keratoconjunctivitis |
||
Administration of ROH-201 ophthalmic solution |
||
Change in clinical signs |
||
| ROHTO Pharmaceutical Co., Ltd. |
| IRB administrated by General incorporated associa tion of ethic committee for clinical trials | |
| 2-12-13, Shinjuku, Shinjuku-ku, Tokyo, Japan, Tokyo | |
+81-3-5050-4268 |
|
| information@centriol-one.com |
No |
none |